Financial Markets collage Northcote Internet Logo
transparent spacer
transparent spacer
 >   > 
transparent spacer
 
curve on page transparent spacer
Northcote Internet Ltd provide Investor Relations Webcasting. Click Here
 
transparent spacer transparent spacer transparent spacer transparent spacer
transparent spacer Home menu end curves
Newsletter
transparent spacer
transparent spacer About Us menu end curves
transparent spacer
transparent spacer Donations menu end curves
transparent spacer
transparent spacer Registrars menu end curves
transparent spacer
transparent spacer Spread Betting menu end curves
transparent spacer
transparent spacer Submit links menu end curves
transparent spacer
transparent spacer transparent spacer
transparent spacer transparent spacer transparent spacer
transparent spacer
transparent spacer
navigation curves Home navigation curves navigation curves By Index navigation curves navigation curves By Sector navigation curves navigation curves Alphabetically navigation curves navigation curves Search navigation curves navigation curves My Portfolio navigation curves
 >  > 
 
Follow northcote_b on Twitter
AstraZeneca
transparent spacer
transparent spacer
transparent spacer
Company Information
Address: Level 9 2 Kingdom Street
London
W2 6BD
Index: To continue showing the FTSE index and sector information we need a license from FTSE International Limited. Will anyone sponsor us to return this data to the site.
Tel: +44 (0)20 7604 8000 Sector:
Fax: +44 (0)20 7604 8270
E-Mail: IR@astrazeneca.com Epic:
Secretary: Adrian Kemp    
Registrar: Equiniti Ltd Updated: 15/04/2013

News from RSS Feed

Fri, 19 Sep 2014 12:10:53 +0100

Study showed AstraZeneca’s exenatide once-weekly suspension for autoinjection provided superior HbA1c reductions vs. twice-daily exenatide (Byetta®) in adults with type 2 diabetes

AstraZeneca today announced 28-week results from DURATION-NEO-1

Company Overview

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

 
Annual Reports
Description Report Date Published Current  
bullet point Annual Report 2012 in PDF 31/12/2012 31/01/2013 Yes  
bullet point Annual Report 2011 in PDF 31/12/2011 2/02/2012 No  
bullet point Annual Report 2010 in PDF 31/12/2010 27/01/2011 No  
bullet point Annual Report 2009 in PDF 31/12/2009 28/01/2010 No  
bullet point Annual Report 2008 in PDF 31/12/2008 29/01/2009 No  
bullet point Annual Report 2007 in PDF 31/12/2007 31/01/2008 No  
bullet point Annual Report 2006 in PDF 31/12/2006 1/02/2007 No  
bullet point Annual Report 2005 in PDF (1.92Mb) 31/12/2005 2/02/2006 No  
bullet point Annual Report 2004 in PDF (0.93Mb) 31/12/2004 27/01/2005 No  
bullet point Annual Report 2003 in PDF (0.8Mb) 31/12/2003 29/01/2004 No  
bullet point Annual Report 2002 part 1 in PDF (0.09Mb) 31/12/2002 30/01/2003 No  
bullet point Annual Report 2002 part 2 in PDF 31/12/2002 30/01/2003 No  
bullet point Annual Report 2001 part 1 in PDF (0.01Mb) 31/12/2001 31/01/2002 No  
bullet point Annual Report 2001 part 2 in PDF 31/12/2001 31/01/2002 No  
bullet point Annual Report 2000 - Part 1 in PDF (0.01Mb) 31/12/2000 7/02/2001 No  
bullet point Annual Report 2000 - Part 2 in PDF (0.02Mb) 31/12/2000 7/02/2001 No  
bullet point Annual Report 1999 - Part 1 in PDF (0.61Mb) 31/12/1999 23/02/2000 No  
bullet point Annual Report 1999 - Part 2 in PDF (0.61Mb) 31/12/1999 23/02/2000 No  
 
Interim Reports
Description Report Date Published Current  
bullet point Interim Results 2012 in PDF 30/06/2012 26/07/2012 Yes  
bullet point Interim Results 2011 figures in PDF 30/06/2011 28/07/2011 No  
bullet point Interim Results 2011 narrative in PDF 30/06/2011 28/07/2011 No  
bullet point Interim Results 2010 - Figures in PDF 30/06/2010 29/07/2010 No  
bullet point Interim Results 2010 - Narrative in PDF 30/06/2010 29/07/2010 No  
bullet point Interim Results 2009 - Figures in PDF 30/06/2009 30/07/2009 No  
bullet point Interim Results 2009 - Narrative in PDF 30/06/2009 30/07/2009 No  
bullet point Interim Results 2008 - Figures in PDF 30/06/2008 31/07/2008 No  
bullet point Interim Results 2008 - Narrative in PDF 30/06/2008 31/07/2008 No  
bullet point Interim Results 2007 - Figures in PDF 30/06/2007 26/07/2007 No  
bullet point Interim Results 2007 - Narrative in PDF 30/06/2007 26/07/2007 No  
bullet point Interim Results 2006 - Figures in PDF 30/06/2006 27/07/2006 No  
bullet point Interim Results 2006 - Narrative in PDF (0.16Mb) 30/06/2006 27/07/2006 No  
bullet point Interim Results 2005 - Figures in PDF (0.09Mb) 30/06/2005 28/07/2005 No  
bullet point Interim Results 2005 - Narrative in PDF (0.06Mb) 30/06/2005 28/07/2005 No  
bullet point Interim Results 2004 - Figures in PDF (0.11Mb) 30/06/2004 22/07/2004 No  
bullet point Interim Results 2004 - Narrative in PDF (0.14Mb) 30/06/2004 22/07/2004 No  
bullet point Interim Results 2003 - Figures in PDF (0.09Mb) 30/06/2003 24/07/2003 No  
bullet point Interim Results 2003 - Narrative in PDF (0.13Mb) 30/06/2003 24/07/2003 No  
bullet point Interim Results 2002 - Figures in PDF (0.05Mb) 30/06/2002 25/07/2002 No  
bullet point Interim Results 2002 - Narrative in PDF (0.05Mb) 30/06/2002 25/07/2002 No  
bullet point Interim Results 2001 - Figures in PDF (0.25Mb) 30/06/2001 26/07/2001 No  
bullet point Interim Results 2001 - Narrative in PDF (0.05Mb) 30/06/2001 26/07/2001 No  
bullet point Interim Results 2000 - Figures in PDF (0.05Mb) 30/06/2000 1/08/2000 No  
bullet point Interim Results 2000 - Narrative in PDF (0.04Mb) 30/06/2000 1/08/2000 No  
bullet point Interim Results 1999 - Figures in PDF (0.02Mb) 30/06/1999 3/08/1999 No  
bullet point Interim Results 1999 - Narrative in PDF (0.03Mb) 30/06/1999 3/08/1999 No  
 
Other Links
Description
bullet point Home
bullet point Site Map
bullet point Investor Relations
bullet point Events Calendar
bullet point Results Index
bullet point Press Releases
bullet point Presentations
bullet point Contacts
bullet point RSS News Feed
       
Dividend History
Type Payment Date Dividend
Interim 18/03/2013 120.5 p
Interim 10/09/2012 58.1 p
Interim 19/03/2012 123.6 p
Interim 12/09/2011 51.9 p
Interim 14/03/2011 116.7 p
Interim 13/09/2010 44.9 p
Interim 15/03/2010 105.4 p
Interim 14/09/2009 36 p
Interim 14/09/2009 0.59 c USD
Interim 14/09/2009 27.8 p
Interim 16/03/2009 104.8 p
Interim 15/09/2008 27.8 p
Interim 17/03/2008 67.7 p
Interim 17/09/2007 25.3 p
Interim 19/03/2007 63 p
Interim 18/09/2006 26.6 p
Interim 20/03/2006 51.8 p
Interim 19/09/2005 21.9 p
Interim 21/03/2005 34.3 p
Interim 20/09/2004 16 p
Interim 6/04/2004 29.4 p
Interim 6/10/2003 15.9 p
Interim 7/04/2003 28.5 p
Interim 7/10/2002 14.7 p
Interim 8/04/2002 33.2 p
Interim 5/10/2001 16.1 p
Interim 9/04/2001 32.1 p
Interim 23/10/2000 15.3 p
Interim 17/04/2000 29.1 p
Interim 25/10/1999 14.2 p

News from RSS Feed

Fri, 19 Sep 2014 12:10:53 +0100

Study showed AstraZeneca’s exenatide once-weekly suspension for autoinjection provided superior HbA1c reductions vs. twice-daily exenatide (Byetta®) in adults with type 2 diabetes

AstraZeneca today announced 28-week results from DURATION-NEO-1
Tue, 16 Sep 2014 16:23:34 +0100

FDA approves MOVANTIK™ (naloxegol) tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain

AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK™ (naloxegol) tablets C-II as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.
Tue, 16 Sep 2014 07:05:00 +0100

AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease

AstraZeneca and Eli Lilly and Company (Lilly) today announced an agreement to jointly develop and commercialise AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.
Wed, 10 Sep 2014 04:42:38 +0100

AstraZeneca to present research from its innovative diabetes portfolio at the 2014 Meeting of the European Association for the Study of Diabetes

AstraZeneca today announced that 29 abstracts covering a range of data from the company’s research and development in diabetes have been accepted for presentation at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, 15-19 September 2014.
Mon, 8 Sep 2014 06:19:20 +0100

Benralizumab Phase II COPD study published in The Lancet Respiratory Medicine

AstraZeneca today announced that The Lancet Respiratory Medicine has published encouraging safety and efficacy data from a Phase IIa study evaluating its novel investigational monoclonal antibody benralizumab in patients with chronic obstructive pulmonary disease (COPD).
Mon, 1 Sep 2014 07:00:00 +0100

New data indicates Brilinta/Brilique™ has the flexibility to be initiated pre-hospital or in hospital in STEMI patients

AstraZeneca today announced the results of the Phase IV ATLANTIC study, which indicates that the profile of BRILINTA/BRILIQUE™ (ticagrelor) is comparable whether administered in a pre-hospital or in-hospital setting to ST segment elevation myocardial infarction (STEMI) patients. The data will be presented during the European Society of Cardiology congress taking place between 30 August and 3 September 2014 in Barcelona.
Thu, 21 Aug 2014 06:26:23 +0100

AstraZeneca announces partnership with Illumina to develop next generation gene sequencing panel for companion diagnostic tests

AstraZeneca today announced that it has entered into a collaboration with gene sequencing company, Illumina, Inc., to develop its next generation sequencing (NGS) platform for companion diagnostic tests applicable across AstraZeneca’s oncology portfolio. In the first instance, AstraZeneca intends to apply Illumina’s cutting-edge technology to a novel companion diagnostic test in pivotal studies for one of its investigational oncology compounds. This is expected to be one of the first NGS-based companion diagnostic tests for a novel drug in the world, and its application could speed the clinical trial process.
Tue, 19 Aug 2014 07:00:42 +0100

AstraZeneca announces positive top-line results from the Phase III programme of CAZ-AVI in patients with complicated intra-abdominal infections (cIAI)

AstraZeneca today announced positive top-line results from RECLAIM-1 and RECLAIM-2, the pivotal Phase III studies investigating the potential of the antibiotic ceftazidime-avibactam (CAZ-AVI) as a treatment for hospitalised adult patients with complicated intra-abdominal infections.
Tue, 19 Aug 2014 07:00:10 +0100

United States Department of Justice closes investigation into PLATO clinical trial for Brilinta

AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with Brilinta (ticagrelor). The government is not planning any further action.
Thu, 14 Aug 2014 05:00:43 +0100

AstraZeneca advances tralokinumab to Phase III in severe asthma

AstraZeneca today announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm.
To continue showing the FTSE index and sector information we need a license from FTSE International Limited. Will anyone sponsor us to return this data to the site.


transparent spacer